Product Information
EUCRISA 2% OINTMENT is a brand product labeled by Pfizer Inc., priced at $12.6465 per GM under NDC 55724021121. Its NADAC has been published 494 times since Apr 19, 2017.
FDA first approved this application on Dec 14, 2016.
Strength
20 mg/g
Manufacturer
Pfizer Inc.NDC
55724021121
Classification
Brand
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
CRISABOROLEApproval Type
New Drug (NDA)
FDA Application
NDA207695FDA Approved
12/14/2016
On Market Since
1/30/2017
Pharmacological Classes
Price Statistics
The NADAC for EUCRISA 2% OINTMENT has been published 494 times since Apr 19, 2017, and over the history we have for it it has risen 35.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.6465 per GM |
|---|---|
| All-time high | $12.6872 (May 14, 2025) |
| All-time low | $9.3589 (Apr 19, 2017) |
| 52-week high | $12.6611 |
| 52-week low | $12.6461 |
| Median price | $11.0714 |
| Average price | $11.0831 |
| Largest weekly change | +6.0% (Jan 10, 2018) |
| Weeks tracked | 494 |
| Tracking since | Apr 19, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
crisaborole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EUCRISA 2% OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for EUCRISA 2% OINTMENT, manufactured by Pfizer Inc., is $12.6465 per GM (NDC 55724021121), effective Sep 30, 2026.
How has the price of EUCRISA 2% OINTMENT changed over time?
Over the history we have for it, the NADAC for EUCRISA 2% OINTMENT has risen 35.1%. It has been tracked across 494 weekly CMS publications since Apr 19, 2017.
What are the highest and lowest recorded NADAC prices for EUCRISA 2% OINTMENT?
Since Apr 19, 2017, the NADAC for EUCRISA 2% OINTMENT has ranged from a low of $9.3589 (Apr 19, 2017) to a high of $12.6872 (May 14, 2025), with a median of $11.0714 per GM.
Are there cheaper alternatives to EUCRISA 2% OINTMENT?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EUCRISA 2% OINTMENT, is $10.7089 per GM — about 15% below EUCRISA 2% OINTMENT.
Who manufactures EUCRISA 2% OINTMENT?
EUCRISA 2% OINTMENT (NDC 55724021121) is labeled by Pfizer Inc., and CMS classifies it as a brand product.